



## NIH-AACR Cancer, Autoimmunity, and Immunology Conference April 15-16, 2019 | Bethesda, MD

**Elizabeth M. Jaffee, MD, FAACR**, AACR Past President; Deputy Director, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

**Elad Sharon, MD, MPH**, Senior Investigator, National Cancer Institute

**Connie Sommers, PhD**, Program Director, National Cancer Institute

**Howard Young, PhD**, Senior Investigator, National Cancer Institute

**Katarzyna (Kasia) Bourcier, PhD**, Program Officer, National Institute of Allergy and Infectious Diseases

**Marie Mancini, PhD**, Program Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases

### AGENDA: APRIL 15, 2019

**9:00 AM**      **Opening remarks and tribute to Stephen Katz**  
**Dinah Singer, PhD**, National Cancer Institute

### KEYNOTE ADDRESS

**9:15 AM**      **T-cell co-stimulation in autoimmune diseases and cancer**  
**Arlene H. Sharpe, MD, PhD, FAACR**, Harvard Medical School

### GASTROINTESTINAL TOXICITIES

**MODERATOR: MICHAEL DOUGAN, MD, PHD**

**9:50 AM**      **GI toxicities of checkpoint blockade**  
**Michael Dougan, MD, PhD**, Massachusetts General Hospital

**10:10 AM**      **Pancreatic exocrine related diarrhea**  
**Erez Baruch, MD**, Sheba Medical Center

**10:30 AM**      **Gastrointestinal and hepatic complications of immune checkpoint inhibitors**  
**Robert S. Bresalier, MD**, MD Anderson Cancer Center

### PANEL DISCUSSION

**Moderator**      **Michael Dougan, MD, PhD**

**Discussants**      **Gastrointestinal Toxicities session speakers and additional panelist:**  
**Mark Anderson, MD, PhD**, University of California, San Francisco

### MOONSHOT ADMINISTRATIVE SUPPLEMENT AWARDEE UPDATE

**11:15 AM**      **Disruption of T-cell tolerance in type 1 diabetes**  
**Mark Anderson, MD, PhD**, University of California, San Francisco

**11:35 AM**      **LUNCH BREAK**

**CYTOKINES, AUTOIMMUNITY, AND IMMUNE-RELATED ADVERSE EVENTS REFRACTORY TO INITIAL THERAPY**  
**MODERATORS: JEFFREY A. SOSMAN, MD, & ELAD SHARON, MD, MPH**

- 12:50 PM**      **IVIG vs. Inflixumab - steroid refractory pneumonitis**  
Jarushka Naidoo, MBBCh, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
- 1:10 PM**      **Multidisciplinary irAE models**  
Kelly Walkovich, MD, C. S. Mott Children's Hospital
- 1:30 PM**      **Balancing immune tolerance with low-dose IL-2**  
David Klatzmann, MD, PhD, Hôpital Pitié-Salpêtrière, Sorbonne Université

**1:50 PM**      **PANEL DISCUSSION**

- Moderators**      Jeffrey A. Sosman, MD, & Elad Sharon, MD, MPH  
**Discussants**      Cytokines, Autoimmunity, and Immune Related Adverse Events session speakers.

**NEUROLOGICAL AND OCULAR TOXICITIES**  
**MODERATOR: DAVID HAFLER, MD, FANA**

- 2:15 PM**      **Unleashing the immune system in the brain**  
David Hafler, MD, FANA, Yale School of Medicine
- 2:35 PM**      **Neurotoxicity associated with immune checkpoint inhibitor treatment**  
Bianca D. Santomasso, MD, PhD, Memorial Sloan Kettering Cancer Center
- 2:55 PM**      **Ocular toxicities**  
Hatice Nida Sen, MD, MHS, National Eye Institute

**3:15 PM**      **PANEL DISCUSSION**

- Moderator**      David Hafler, MD, FANA  
**Discussants**      Neurological and Ocular Toxicities session speakers.

**3:40 PM**      **BREAK**

**KEYNOTE ADDRESS**

- 4:00 PM**      **Immuno-oncology combination clinical trials**  
Elizabeth M. Jaffee, MD, FAACR, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

**COMBINATION THERAPIES**  
**MODERATOR: ELIZABETH M. JAFFEE, MD, FAACR**

- 4:30 PM**      **Toxicities of radiation-immunotherapy combinations**  
Jonathan D. Schoenfeld, MD, MPH, Dana-Farber Cancer Institute
- 4:50 PM**      **Regulatory perspectives on combination immuno-oncology trials and approvals**  
Nicole Drezner, MD, U.S. Food and Drug Administration

**5:10 PM**      **PANEL DISCUSSION**

- Moderator**      Elizabeth M. Jaffee, MD, FAACR  
**Discussants**      Combination Therapies session speakers.

**5:35 PM**      **POSTER SESSION & RECEPTION**

Join us on the FAES Terrace for a Poster Session and Networking Reception

**7:00 PM**      **ADJOURN**



**NIH-AACR Cancer, Autoimmunity, and Immunology Conference**  
April 15-16, 2019 | Bethesda, MD

**AGENDA: APRIL 16, 2019**

9:00 AM Welcoming remarks

**SKIN TOXICITIES AND RHEUMATOLOGY**  
**MODERATOR: ROBERT H. CARTER, MD**

9:05 AM **Rheumatic adverse effects of immune checkpoint inhibitors**  
Xavier Mariette, MD, PhD, Hôpital Bicêtre, Université Paris-Sud

9:25 AM **Sicca as a complication of immune checkpoint inhibition: Is it Sjögren's Syndrome?**  
Blake Warner, DDS, PhD, MPH, National Institute of Dental and Craniofacial Research

9:45 AM **Skin toxicities from immune checkpoint inhibitors**  
Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute

10:05 AM **Mechanisms of autoimmunity association with cancer**  
Antony Rosen, MBChB, BSc (Hon.), Johns Hopkins School of Medicine

**10:25 AM PANEL DISCUSSION**

**Moderator** Robert H. Carter, MD  
**Discussants** Skin Toxicities and Rheumatology session speakers.

10:50 AM **BREAK**

**MOONSHOT ADMINISTRATIVE SUPPLEMENT AWARDEE UPDATE**

11:10 AM **Assessing roles for dendritic cells in immune-related adverse events with checkpoint inhibitor therapy**  
Stephanie Watowich, PhD, MD Anderson Cancer Center

**THE BIG PICTURE: APPROACHING IMMUNE-RELATED ADVERSE EVENTS FROM MULTIPLE DATA STREAMS**  
**MODERATOR: GIORGIO TRINCHIERI, MD**

11:35 AM **Immune-related adverse events**  
Douglas B. Johnson, MD, Vanderbilt-Ingram Cancer Center

11:55 AM **Alliance-NCI immune-related adverse events biorepository**  
David Kozono, MD, PhD, Dana-Farber Cancer Institute

12:15 PM **Approaching irAEs from multiple data streams: Regulatory considerations**  
Meredith Chuk, MD, U.S. Food and Drug Administration

12:35 PM **LUNCH BREAK**

## KEYNOTE ADDRESS

**1:45 PM**      **The role of the microbiome in response and toxicity to therapy**  
Jennifer Wargo, MD, MMSc, MD Anderson Cancer Center

## 2:15 PM      PANEL DISCUSSION

**Moderator**      Giorgio Trinchieri, MD  
**Discussants**      Meredith Chuk, MD  
Douglas B. Johnson, MD  
David Kozono, MD, PhD  
Jennifer Wargo, MD, MMSc

## CELL-BASED IMMUNOTHERAPY

**2:45 PM**      **Adverse events of CAR-T cell therapy for hematologic malignancies**  
David L. Porter, MD, University of Pennsylvania Perelman School of Medicine

**3:10 PM**      **CAAR-T for pemphigus vulgaris**  
Michael Milone, MD, PhD, University of Pennsylvania Perelman School of Medicine

## 3:35 PM      BREAK

## NON-CLINICAL MODELS

**MODERATORS: JOHN LEIGHTON, PHD, & JULIE SCHNEIDER, PHD**

**3:55 PM**      **Autoimmunity following cancer treatment, more questions than answers**  
Jeff Bluestone, PhD, Parker Institute for Cancer Immunotherapy

**4:15 PM**      **Understanding IO toxicities using syngeneic immunocompetent mouse models: Lessons, opportunities, and challenges**  
Gregory L. Beatty, MD, PhD, University of Pennsylvania Perelman School of Medicine

**4:35 PM**      **Preventing immunotherapy related adverse events by targeting CD24-Siglec signaling pathway**  
Pan Zheng, MD, PhD, University of Maryland, Baltimore

**4:55 PM**      **Use of immune humanized mice in assessment of biological drug product adverse events and immunogenicity**  
Kristina E. Howard, DVM, PhD, U.S. Food and Drug Administration

## 5:15 PM      PANEL DISCUSSION

**Moderators**      John Leighton, PhD, & Julie Schneider, PhD  
**Discussants**      Non-clinical Models session speakers and additional panelist:  
Stephanie Watowich, PhD

## 5:45 PM      ADJOURN

